The American and German laboratories Pfizer and BioNTech announced that they had carried out a first interim analysis of their phase 3 trial on a vaccine against the new coronavirus, the last before an application for approval.
The two laboratories claim that the vaccine, as research currently stands, is “90% effective.” Vaccine efficacy which was measured by comparing the number of participants infected with the new coronavirus in the group that received the vaccine and in that under placebo, seven days after the second dose and 28 days after the first, they explained in a joint press release.
“More than eight months after the start of the worst pandemic in more than a century, we believe that this step represents a significant step forward for the world in our battle against Covid-19,” said the Chairman and CEO of Pfizer, Albert Bourla. “The first set of results from our Phase 3 Covid-19 vaccine trial provides initial evidence of our vaccine’s ability to prevent Covid-19,” he adds.
US President Donald Trump on Monday greeted “excellent news”, while his successor, Joe Biden sees a sign of “hope” in the announcement.
Shortly after the announcement from the US and German laboratories, European markets were propelled upwards, which recalls that at midday, European markets had their best performance in one session in six months.